New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For PCL;LH;DNB;SNTA;ESI;FLIR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
14:22 EDTLHLabCorp price target raised to $130 from $113 at Craig-Hallum
Subscribe for More Information
November 24, 2014
17:28 EDTFLIRFLIR Systems announces favorable verdict in litigation matter
FLIR Systems (FLIR) announced that the company and its subsidiary, Indigo Systems, now known as FLIR Commercial Systems, have received a favorable verdict in a previously disclosed lawsuit filed by Raytheon (RTN). A jury in the United States District Court for the Eastern District of Texas rejected Raytheon's allegations that Indigo, prior to its acquisition by FLIR in 2004, and FLIR misappropriated 31 trade secrets owned by Raytheon. The jury determined that 27 of the 31 alleged trade secrets were not in fact Raytheon trade secrets and that neither FLIR nor Indigo misappropriated any of 31 trade secrets that were claimed. No damages were awarded against FLIR and Indigo. The court will decide whether or not to award FLIR and Indigo their attorney's fees as the prevailing parties under the Texas Theft Liability Act.
November 21, 2014
08:48 EDTLHLabCorp completes acquisition of LipoScience
Subscribe for More Information
November 20, 2014
09:32 EDTLHLipoScience to host special shareholder meeting
Subscribe for More Information
November 19, 2014
07:04 EDTSNTASynta Pharmaceuticals presents preclinical results from Hsp90 platform
Synta Pharmaceuticals announced that a poster highlighting preclinical results from its Hsp90 inhibitor Drug Conjugate platform is being presented at the 26th EORTC-NCI-AACR Symposium in Barcelona. “This poster highlights our ongoing evaluation of multiple candidates from the HDC platform. The preclinical results for our lead candidates not only demonstrate broad activity across several tumor types, but also the ability for HDCs to induce prolonged antitumor effects as compared to well-established cytotoxic agents,” said Weiwen Ying, Vice President, Discovery Chemistry at Synta. “In addition, the platform is not limited to using traditional cytotoxic therapeutics as payloads. A number of commonly used small molecule anticancer agents may also be incorporated, including tyrosine kinase inhibitors, proteosome inhibitors, small molecule immunotherapeutics, and other molecularly targeted agents. By leveraging the preferential retention characteristic of the Hsp90 targeting arm of an HDC in tumors, intratumoral exposure and antitumor potency for a wide array of payloads can be potentially improved." "We are encouraged by the progress the team has achieved to date with candidates arising from the HDC platform and the promise that the platform holds for both internal development and partnerships,” said Anne Whitaker, President and CEO of Synta. “We continue to evaluate options for efficiently advancing candidates from this platform and look forward to providing updates in the future.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use